Terms: = Prostate cancer AND FANCE, 2178, ENSG00000112039, FAE AND Treatment
5 results:
1.
Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
[No Abstract] [Full Text] [Related]
2. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
3. First clinical experiences with a high field 1.5 T MR linac.
Bertelsen AS; Schytte T; Møller PK; Mahmood F; Riis HL; Gottlieb KL; Agergaard SN; Dysager L; Hansen O; Gornitzka J; Veldhuizen E; ODwyer DB; Christiansen RL; Nielsen M; Jensen HR; Brink C; Bernchou U
Acta Oncol; 2019 Oct; 58(10):1352-1357. PubMed ID: 31241387
[No Abstract] [Full Text] [Related]
4. The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature.
Di Bella G; Mascia F; Colori B
Neuro Endocrinol Lett; 2013; 34(6):523-8. PubMed ID: 24378460
[TBL] [Abstract] [Full Text] [Related]
5. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review.
Caro JJ; Salas M; Ward A; Goss G
Cancer; 2001 Jun; 91(12):2214-21. PubMed ID: 11413508
[TBL] [Abstract] [Full Text] [Related]
